Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DWC202405 + DWC202313** is an investigational **combination drug therapy** currently in phase III clinical trials for the treatment of **essential hypertension**. This combination is being studied specifically for patients whose hypertension is inadequately controlled with DWC202405 alone. The precise pharmacologic classes, individual generic names, and mechanisms of DWC202405 and DWC202313 are not provided in public sources; both are code-named investigational agents from Daewoong Pharmaceutical. The combination is evaluated in randomized, double-blind clinical trials as part of a strategy to improve blood pressure control in this patient population[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DWC202405 + DWC202313.